Tags

Type your tag names separated by a space and hit enter

Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM.
Am J Kidney Dis. 1998 Apr; 31(4):666-73.AJ

Abstract

Hypercholesterolemia is a major determinant of the decline of renal function in patients with diabetes. Apolipoprotein E polymorphism may influence the metabolism of lipoprotein in diabetic patients. The purpose of this study was to investigate the association between genetic polymorphisms in apolipoprotein E and the progression of diabetic nephropathy in patients with non-insulin-dependent diabetes mellitus over a 10-year period (13 to 37 years; median, 20 years). Subjects with a stable renal function without overt proteinuria had a higher cholesterol level, lower incidences of hypertension and proliferative diabetic retinopathy, and a higher frequency of the E4 allele than subjects with a decline in renal function (end-stage renal failure requiring dialysis treatment). In the diabetic patients, the apolipoprotein E4 carriers had a higher cholesterol level than did the noncarriers. The survival rate from renal disease in the apolipoprotein E4 carriers was higher than in the noncarriers among the diabetic patients. Apolipoprotein E polymorphism and hypertension were identified as independent risk factors for the progression to renal failure. Results indicate that apolipoprotein E polymorphism is associated with the progression of diabetic nephropathy. Presence of the apolipoprotein E4 allele is a protective factor, and other alleles are risk factors.

Authors+Show Affiliations

Department of Medicine (II), Nigata University School of Medicine, Japan. hkimura@fmsrsa.fukui-med.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

9531184

Citation

Kimura, H, et al. "Apolipoprotein E4 Reduces Risk of Diabetic Nephropathy in Patients With NIDDM." American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, vol. 31, no. 4, 1998, pp. 666-73.
Kimura H, Suzuki Y, Gejyo F, et al. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis. 1998;31(4):666-73.
Kimura, H., Suzuki, Y., Gejyo, F., Karasawa, R., Miyazaki, R., Suzuki, S., & Arakawa, M. (1998). Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 31(4), 666-73.
Kimura H, et al. Apolipoprotein E4 Reduces Risk of Diabetic Nephropathy in Patients With NIDDM. Am J Kidney Dis. 1998;31(4):666-73. PubMed PMID: 9531184.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. AU - Kimura,H, AU - Suzuki,Y, AU - Gejyo,F, AU - Karasawa,R, AU - Miyazaki,R, AU - Suzuki,S, AU - Arakawa,M, PY - 1998/4/8/pubmed PY - 1998/4/8/medline PY - 1998/4/8/entrez SP - 666 EP - 73 JF - American journal of kidney diseases : the official journal of the National Kidney Foundation JO - Am J Kidney Dis VL - 31 IS - 4 N2 - Hypercholesterolemia is a major determinant of the decline of renal function in patients with diabetes. Apolipoprotein E polymorphism may influence the metabolism of lipoprotein in diabetic patients. The purpose of this study was to investigate the association between genetic polymorphisms in apolipoprotein E and the progression of diabetic nephropathy in patients with non-insulin-dependent diabetes mellitus over a 10-year period (13 to 37 years; median, 20 years). Subjects with a stable renal function without overt proteinuria had a higher cholesterol level, lower incidences of hypertension and proliferative diabetic retinopathy, and a higher frequency of the E4 allele than subjects with a decline in renal function (end-stage renal failure requiring dialysis treatment). In the diabetic patients, the apolipoprotein E4 carriers had a higher cholesterol level than did the noncarriers. The survival rate from renal disease in the apolipoprotein E4 carriers was higher than in the noncarriers among the diabetic patients. Apolipoprotein E polymorphism and hypertension were identified as independent risk factors for the progression to renal failure. Results indicate that apolipoprotein E polymorphism is associated with the progression of diabetic nephropathy. Presence of the apolipoprotein E4 allele is a protective factor, and other alleles are risk factors. SN - 1523-6838 UR - https://www.unboundmedicine.com/medline/citation/9531184/Apolipoprotein_E4_reduces_risk_of_diabetic_nephropathy_in_patients_with_NIDDM_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0272-6386(98)00099-7 DB - PRIME DP - Unbound Medicine ER -